Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.

Overview
Date Founded

1995

Headquarters

500 ARSENAL STREET, WATERTOWN, MA, 02472

Type of Company

Public

Employees (Worldwide)

141

Industries

Pharmaceuticals
Hospitals & Patient Services
Chemicals
Biotechnology

Company Description

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Contact Data
Trying to get in touch with decision makers at Enanta Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President, Chief Executive Officer & Director

Chief Financial Officer & Senior Vice President-Finance & Administration

Senior Vice President, Research & Development & Chief Scientific Officer

Senior Vice President, Chief Medical Officer

Senior Vice President, New Product Strategy & Development

Head-Investor Relations & Communications

Clinical Operations Director

Director, Investor Relations

Board of Directors

Former Executive Chairman at Infectious Disease Research Institute

Former Chief Financial & Accounting Officer at Biocept, Inc.

Former Chief Medical Officer & Executive Vice President at Cephalon, Inc.

Co-Founder at EGS Healthcare Capital Partners LLC

Venture Partner at ARCH Venture Partners

Former Chief Executive Officer at Valeritas, Inc.

Paths to Enanta Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Enanta Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Krensavage Asset Management (KAM) seeks superior absolute returns primarily through long term capital appreciation with a focus on capital preservation. The firm purchases securities they believe trade below their intrinsic value and selling securities they believes trade above their intrinsic value. KAM's investments focus on the purchase and sell of equity securities of public companies in the healthcare industry. The firm may also invest in other industries, asset classes and markets that are poised for superior performance.

Details Hidden

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund firm which focuses primarily on the health care and consumer sectors. They invest predominantly in equities and can be opportunistic across the capital structure. The firm seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated returns. They maintain significant position and portfolio level hedges in an effort to mitigate basis and market risks. Armistice Capital employs a bottom-up analysis, assessing all components of the company’s capital structure and aims to take larger positions where the greatest potential risk adjusted return exists. Armistice Capital’s Domestic Fund and the Offshore Fund, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing in distressed debt, value equities and event equities. In all of its investing activities, the Funds will seek to emphasize capital preservation and will seek to mitigate risk through various hedging strategies at both the position and portfolio levels.

Details Hidden

Fairmount Funds Management LLC is a private company headquartered in Philadelphia, PA, with a presence in the United States, that provides investment advice. It was founded in 2016.

Recent Transactions
Details Hidden

Enanta Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onEnanta Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onEnanta Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onEnanta Pharmaceuticals, Inc. issued USD Common Stock

Managing Partner

Advised onEnanta Pharmaceuticals, Inc. issued USD Common Stock

Co-Chair, Life Sciences Group

Advised onEnanta Pharmaceuticals, Inc. issued USD Common Stock

Managing Director-Equity Capital Markets

Advised onEnanta Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Davis Polk & Wardwell LLP

Advisor

Managing Partner at MacDougall Advisors, Inc.

Clients

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Key Stats and Financials As of 2020
Market Capitalization
$845M
Total Enterprise Value
$536M
Earnings Per Share
$-1.81
Revenue
$122M
TEVNet Income
-14.81x
Enterprise Value / Sales
4.37x
Debt TEV
0.02x
Total Equity
$456M
Total Debt
$9.58M
Net Profit
$-36.2M
EBITDAMargin
-31.02%
EBITDA
$-38M
Three Year Compounded Annual Growth Rate Of Revenue
6.01%
Non-Profit Donations & Grants
$1,000 - $4,999
2012
Investors
Details Hidden

Alpha's private equity investment strategies are customized for their clients' requirements. Their investment objective is to create value. They employ an active portfolio management style and leverage their wide-ranging industry network. Alpha constructs comprehensive private equity portfolios diversified by stage, geography, industry, vintage, fund manager as well as primary and secondary investments. They have a particular geographical focus of Central and Eastern Europe, Europe, Israel, and the US.Alpha invests at various stages such as MBOs, MBIs, early-stage, expansion, development capital, mezzanine, bridge finance, as well as providing seed capital. Some of the industrial sectors they are target are biotechnology, computer related, consumer related, electronics, Internet technology, medical, life sciences, health related, telecommunications, and communications. Typically the firm's minimum investment size is EUR 3 million and their minimum equity stake is EUR 3 million.

Details Hidden

SLPEP manages Swiss Life's proprietary private equity portfolio. They make investments in private equity funds across all sectors.

Details Hidden

BioVentures Investors seeks investment opportunities in healthcare and life sciences companies located in the US. The fund provides financing for seed , early and expansion stage capital requirements with an investment size ranging from $3 to $10 million. It takes an active role on the board of directors.

Suppliers
Open Orphan Plc Medical Support Services | London, United Kingdom

Open Orphan Plc provides pharmaceutical development services. The company was founded on February 1, 2011 and is headquartered in London, the United Kingdom.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Gilead Sciences, Inc. Biotechnology - Foster City, CA

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Enanta Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Enanta Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Enanta Pharmaceuticals, Inc..